Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05717400
Phase
PHASE4
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Given by vein (IV)
  • Atezolizumab — DRUG
    Given by vein (IV)
  • Sofosbuvir — DRUG
    Given by PO
  • Velpatasvir — DRUG
    Given by PO
  • Voxilaprevir — DRUG
    Given by PO
  • Ribavirin — DRUG
    Given by PO

Study Details

To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.

Key Dates

Start date
Mar 17, 2023
Status verified
Nov 2024
Primary completion
Aug 29, 2024
Completion
Aug 29, 2024

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DAA therapy plus Bevacizumb and Atezolizumab
    Participants will receive bevacizumab and atezolizumab about every 3 weeks as part of the standard of care HCC treatment that is managed by your cancer doctor. In addition, Participants will continue receiving your standard of care DAAs (either sofosbuvir + velpatasvir or sofosbuvir + velpatasvir + voxilaprevir)

Primary Outcome Measure

Overall Response Rate [ Time Frame: 9 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
M D Anderson Cancer Center· Houston, TX

Related Studies